GOSS - Gossamer Bio, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Gossamer Bio, Inc.

3013 Science Park Road
Suite 200
San Diego, CA 92121
United States
858-684-1300
http://www.gossamerbio.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees118

Key Executives

NameTitlePayExercisedYear Born
Mr. Faheem HasnainCo-Founder & Chairman767.3kN/A1958
Dr. Sheila K. Gujrathi M.D.Co-Founder, Pres, CEO & Director767.3kN/A1970
Mr. Bryan GiraudoChief Financial Officer532.51kN/A1976
Mr. Christian WaageExec. VP, Gen. Counsel & Sec.551.3kN/A1967
Dr. Jakob DupontChief Medical Officer108.33kN/A1965
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. It is developing GB001, an oral antagonist of prostaglandin D2 receptor 2 that is in Phase IIb clinical trial for the treatment of moderate-to-severe eosinophilic asthma, as well as that has completed Phase I clinical trial for chronic rhinosinusitis with nasal polyps, without nasal polyps, and chronic spontaneous urticarial; GB002, a platelet-derived growth factor, receptor kinase inhibitor that is in Phase I clinical trial for the treatment of pulmonary arterial hypertension; GB004, an oral small molecule that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and GB1275, an oral small molecule for the treatment of oncology indications. It has license agreement with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was founded in 2015 and is headquartered in San Diego, California.

Corporate Governance

Gossamer Bio, Inc.’s ISS Governance QualityScore as of October 4, 2019 is 9. The pillar scores are Audit: 2; Board: 9; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.